SCHEMBL5366373

SCHEMBL5366373

Cc1c(Br)ccc2c1C(=Cc1c(F)cccc1C(F)(F)F)C(=O)N2

nearest known ligand 0.36

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
KDR P35968 4/20 0.36
PDPK1 O15530 1/20 0.36
RET P07949 4/20 0.35
PDGFRB P09619 3/20 0.34
EGFR P00533 2/20 0.34
PDGFRA P16234 1/20 0.34
CCNE2 O96020 1/20 0.34
CCNE1 P24864 1/20 0.34
CDK2 P24941 1/20 0.34
NPC1 O15118 1/20 0.33
ERBB2 P04626 2/20 0.33
MEN1 O00255 1/20 0.32
KMT2A Q03164 1/20 0.32
FGFR1 P11362 1/20 0.32
FLT3 P36888 1/20 0.32
HTR2C P28335 4/20 0.32
HTR2B P41595 4/20 0.32
HTR2A P28223 3/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7130447 0.90 KDR (0.40) KDRPDPK1RETPDGFRBEGFR
SCHEMBL5357855 0.84 MEN1 (0.39) KDRPDPK1RETCCNE2CCNE1
SCHEMBL7138178 0.83 CES1 (0.35) KMT2AFLT3HTR2CHTR2BHTR2A
SCHEMBL7134441 0.83 MYC (0.43) KDRPDPK1RETNPC1MEN1
SCHEMBL7132017 0.79 NPC1 (0.44) KDRPDPK1RETPDGFRBEGFR
SCHEMBL7131343 0.79 NPC1 (0.56) KDRPDPK1RETCCNE2CCNE1
SCHEMBL5366324 0.78 MEN1 (0.44) KDRPDGFRBCCNE1CDK2MEN1
SCHEMBL5377075 0.77 NPC1 (0.42) KDRPDPK1RETPDGFRBEGFR
SCHEMBL5368774 0.76 MEN1 (0.37) KDRRETPDGFRBPDGFRACCNE2
SCHEMBL7136994 0.74 MAOA (0.44) KDRPDPK1RETPDGFRBMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7202265-B2 Indolinone combinatorial libraries and related products and methods for the treatment of disease SUGEN, INC. (US) 2007-04-10 US disclosed
US-20050197382-A1 Indolinone combinatorial libraries and related products and methods for the treatment of disease SUGEN, INC. 2005-09-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050197382-A1 Indolinone combinatorial libraries and related products and methods for the treatment of disease FRK, PTK2, DSTYK KDR 239/4885PDPK1 31/4885RET 283/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.